Phase III Randomized Controlled Trial Comparing the Survival of Patients With Unresectable Hepatocellular Carcinoma Treated With Nolatrexed or Doxorubicin

2007280 citationsJournal Article

Authors

NOL showed minimal activity in this phase III trial. Further exploration at this dose and schedule in HCC is not warranted.

Good health and well-being

Published in: Journal of Clinical Oncology

Volume 25, Issue 21, pp. 3069-3075

Field-Weighted Citation Impact: 9.90